Everolimus: A Challenging Drug in the Treatment of Multifocal Inoperable Cardiac Rhabdomyoma

被引：59

作者：

Demir, Haci Ahmet ^{[1
]}

Ekici, Filiz ^{[2
]}

Erdem, Arzu Yazal ^{[1
]}

Emir, Suna ^{[1
]}

Tunc, Bahattin ^{[1
]}

机构：

[1] Ankara Childrens Hematol Oncol Educ & Res Hosp, Dept Pediat Hematol Oncol, TR-06100 Ankara, Turkey

[2] Ankara Childrens Hematol Oncol Educ & Res Hosp, Dept Pediat Cardiol, TR-06100 Ankara, Turkey

来源：

PEDIATRICS | 2012年 / 130卷 / 01期

关键词：

cardiac; heart; rhabdomyoma; newborn; child; everolimus; TUBEROUS SCLEROSIS; TUMORS; CHILDREN; INFANCY; MTOR;

D O I：

10.1542/peds.2011-3476

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morbidity and mortality. Herein, we report a newborn infant with multifocal cardiac rhabdomyomas treated with everolimus. The optimal dose of the drug was 0.25 mg 2 times per day, 2 days per week. Patients with inoperable cardiac rhabdomyomas and with symptoms may be candidates for everolimus treatment. Pediatrics 2012; 130: e243-e247

引用

页码：E243 / E247

页数：5

共 24 条

[1]

Arnaiz P, 2006, REV MED CHILE, V134, P1135

[2] PRIMARY MALIGNANT CARDIAC TUMORS IN CHILDREN [J].